Dr Santiago Escrivá-de-Romani speaks to ecancer about the primary results from a phase 2a study of zanidatamab, palbociclib and fulvestrant in HER2+/HR+ metastatic breast cancer (mBC).

Dr Escrivá-de-Romani says that a previous analysis of the current single-arm, phase 2a study demonstrated antitumour activity and a tolerable safety profile for zanidatamab, palbociclib and fulvestrant in heavily pretreated patients with HER2+/HR+ mBC.

This study aimed to report the primary endpoint of progression-free survival at 6 months and other endpoints.

The results of this study support the further development of a novel chemotherapy-free treatment regimen for heavily pretreated patients with HER2+/HR+ mBC. This treatment regimen showed promising progression-free survival at 6 months and median progression-free survival with durable responses.